TOL102

For novel oncology therapies.

Bone marrow and bone stem cell transplant therapies provide clinicians with alternatives for mitigating various types of leukemia and blood cancers. Our therapeutic antibody technology has been applied in two unique life-saving bone marrow / bone stem cell applications, which the company plans to pursue for possible commercialization.

• Pediatric acute lymphoblastic leukemia (Philadelphia + ALL): For children with ALL, bone marrow transplants using matched sibling donors has been associated with better long-term survival. Without a matched sibling donor, however, many young patients are precluded from this promising therapy. In an experimental trial, our therapeutic antibody was used as part of a protocol using unrelated and/or partially mismatched related donors. The study concluded that the protocol using our antibody was a reasonable and recommended course of treatment for patients without matched siblings, thus opening up a new treatment alternative for these young patients.
  
  
• Hematologic malignancy high risk patients: In a study of adults with high-risk hematologic malignancy, our therapeutic antibody was applied in a unique bone stem cell treatment targeted at patients who would otherwise be ineligible for such a transplant due to the toxic pre-conditioning required (chemotherapy and/or irradiation). The study concluded that the use of our therapeutic in a conditioning regimen with a single agent chemotherapy was able to achieve durable bone stem cell engraftment, and long-term survival in high risk patients who would not have qualified for conventional pre-conditioned bone stem cell therapy.